Your browser doesn't support javascript.
loading
Very-high-risk localized prostate cancer: definition and outcomes.
Sundi, D; Wang, V M; Pierorazio, P M; Han, M; Bivalacqua, T J; Ball, M W; Antonarakis, E S; Partin, A W; Schaeffer, E M; Ross, A E.
Afiliação
  • Sundi D; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Wang VM; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Pierorazio PM; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Han M; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Bivalacqua TJ; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Ball MW; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Antonarakis ES; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Partin AW; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Schaeffer EM; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Ross AE; Brady Institute of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Prostate Cancer Prostatic Dis ; 17(1): 57-63, 2014 Mar.
Article em En | MEDLINE | ID: mdl-24189998
ABSTRACT

BACKGROUND:

Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially-some will have excellent cancer-specific survival, whereas others will experience early metastasis even after aggressive local treatments. Current nomograms, which yield continuous risk probabilities, do not separate high-risk PCa into distinct sub-strata. Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy.

METHODS:

We queried the Johns Hopkins radical prostatectomy database to identify 753 men with NCCN high-risk localized PCa (Gleason sum 8-10, PSA >20 ng ml(-1), or clinical stage ≥T3). Twenty-eight alternate permutations of adverse grade, stage and cancer volume were compared by their hazard ratios for metastasis and cancer-specific mortality. VHR criteria with top-ranking hazard ratios were further evaluated by multivariable analyses and inclusion of a clinically meaningful proportion of the high-risk cohort.

RESULTS:

The VHR cohort was best defined by primary pattern 5 present on biopsy, or ≥5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. These criteria encompassed 15.1% of the NCCN high-risk cohort. Compared with other high-risk men, VHR men were at significantly higher risk for metastasis (hazard ratio 2.75) and cancer-specific mortality (hazard ratio 3.44) (P<0.001 for both). Among high-risk men, VHR men also had significantly worse 10-year metastasis-free survival (37% vs 78%) and cancer-specific survival (62% vs 90%).

CONCLUSIONS:

Men who meet VHR criteria form a subgroup within the current NCCN high-risk classification who have particularly poor oncological outcomes. Use of these characteristics to distinguish VHR localized PCa may help in counseling and selection optimal candidates for multimodal treatments or clinical trials.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article